ライフサイエンスコーパス: microsome

1 e same pattern ex vivo (COS-1) and in vitro (microsomes).

2 lysates (e.g., human T47D breast cancer cell microsomes).

3 incubations with HLMs and monkey and rabbit microsomes.

4 native tetramer band in insect cell derived microsomes.

5 ate proteins during their translocation into microsomes.

6 lypeptide lengths, in mammalian cells and ER microsomes.

7 ate stability (t1/2 = 44 min) in mouse liver microsomes.

8 -fold increases in half-lives in mouse liver microsomes.

9 in vitro metabolic stability in human liver microsomes.

10 er metabolic stability than 5 in human liver microsomes.

11 PZQ)Cr(CO)3 (1 and 2), by use of human liver microsomes.

12 inhibit isomerohydrolase activity in the RPE microsomes.

13 t this compound is stable in serum and liver microsomes.

14 (S)-mephenytoin hydroxylation in human liver microsomes.

15 PDH type 2 and good stability in mouse liver microsomes.

16 d biotransformation assay based on rat liver microsomes.

17 lic stability in the presence of human liver microsomes.

18 degrees C and 33 degrees C using control rat microsomes.

19 t of several crocins when expressed in yeast microsomes.

20 rohydrolase activity was assessed in the RPE microsomes.

21 hepsin S activity and very poor stability to microsomes.

22 or caffeine-induced Ca(2)(+) release from SR microsomes.

23 on of RyR1-mediated Ca(2)(+) release from SR microsomes.

24 ed RyR-mediated Ca(2)+ leak from skeletal SR microsomes.

25 nd co-fractionates with EGFR in high density microsomes.

26 pironetin's major metabolite in human liver microsomes.

27 nd retinal G protein-coupled receptor in RPE microsomes.

28 reactivated upon addition of BAK-containing microsomes.

29 bolism observed in phospholipid-depleted RPE microsomes.

30 ith MAM-derived DRMs but not with those from microsomes.

31 ivatives significantly in pooled human liver microsomes.

32 re identified by incubation with human liver microsomes.

33 n native cardiac sarcoplasmic reticulum (SR) microsomes.

34 tionated predominantly with mitochondria and microsomes.

35 oxypalmitate, using CYP77A6-expressing yeast microsomes.

36 ely potent under hypoxia and stable to liver microsomes.

37 which is about 5 times more than that in the microsomes.

38 ence of UDP-Xyl was also identified in these microsomes.

39 ng G6P and increasing P(i) concentrations in microsomes.

40 slation and translocation system with canine microsomes.

41 complete absence of UGT1A proteins in liver microsomes.

42 ism in human intestinal microsomes and liver microsomes.

43 ated myoblasts, myotubes, or skeletal muscle microsomes.

44 e more metabolically stable in human hepatic microsomes.

45 insect cells and was isolated as insect cell microsomes.

46 th selected lumenal factors inside mammalian microsomes.

47 was detected in dog, human, and monkey liver microsomes.

48 er microsomes than in human and monkey liver microsomes.

49 e majority of this activity co-purified with microsomes.

50 or, [3H]MAEA, bound specifically to the FAAH microsomes.

51 etitively displaced the [3H]MAEA on the FAAH microsomes.

52 long-term PrP-res production than suspended microsomes.

53 e effect of 10.1 was measured in human liver microsomes.

54 ly improved metabolic stability to rat liver microsomes.

55 etabolism assays performed using human liver microsomes.

56 reased RyR1-mediated Ca(2+) release from SkM microsomes.

57 tivity, and its metabolic stability in mouse microsomes.

58 ibition of cytochrome P450s from human liver microsomes.

59 urafenib in in vitro assays with human liver microsomes.

60 itro metabolic turnover of fenclozic acid in microsomes.

61 In rat liver microsomes, 2-(3-mercaptopropyl)pentanedioic acid (2-MPP

62 In human liver microsomes, 4-oxo-atRA formation was supported by NAD(+)

63 inhibits lysosome cathepsins and APC-derived microsome activity in vitro and partially inhibits lysos

64 tabolic stabilities in mouse and human liver microsomes, along with acceptable cytotoxicity profiles.

65 abromobisphenol A, and bisphenol S) in liver microsome and cell models.

66 lation and good metabolic stability in liver microsome and hepatocyte assays.

67 ng from 20.1 (+/-2.8)% to 71.3 (+/-19.5)% in microsomes and 24.0 (+/-1.5)% to 82.5 (+/-14.0)% in bloo

68 inidine, two prototypic substrates, in liver microsomes and a reconstituted enzyme system with K(i) a

69 OC14 exhibited high stability in mouse liver microsomes and blood plasma, low intrinsic microsome cle

70 nd FTUCAs with proteins present in rat liver microsomes and bovine blood plasma.

71 nstrated by two-phase fractionation of plant microsomes and by in vivo detection of AtCPK5-GFP fusion

72 The results obtained with sealed microsomes and CHO cells indicate that Dol-P, formed fro

73 I metabolic stability studies in mouse liver microsomes and compared to cocaine in locomotor activity

74 oncentration, and stoichiometry in rat liver microsomes and cultured cells.

75 Human liver microsomes and CYP1A2 supersomes showed the highest bioa

76 ssment of metabolic stability in human liver microsomes and cytochrome P450 inhibition potential.

77 metabolites was not observed in medaka liver microsomes and cytochrome P450 was not induced with AP/A

78 otein UV photocross-linking studies in rough microsomes and demonstrate that numerous ER integral mem

79 s compound was metabolically stable in liver microsomes and displayed anti-tumor activity in xenograf

80 ically stable in rat plasma and in rat liver microsomes and efficacious in rats when given orally to

81 pids, activity of HMG-CoA reductase in liver microsomes and EPA+DHA incorporation in liver, heart and

82 hadone into its main metabolite by rat liver microsomes and for demonstrating the potential of known

83 HP for deiodinase inhibition using rat liver microsomes and for peroxisome proliferator-activated rec

84 liver microsomes, metabolism by human liver microsomes and hepatocytes, and in vivo disposition in r

85 oligomers was investigated using human liver microsomes and human liver cytosol.

86 able to profile active enzymes in rat liver microsomes and identify pyrethroid-metabolizing enzymes

87 udies were investigated in rat and dog liver microsomes and in the filamentous fungus Cunninghamella

88 abolic stability of 6a and 6m in mouse liver microsomes and in vivo pharmacokinetic profiles in plasm

89 selective PCB biotransformation by rat liver microsomes and in vivo.

90 and favorable metabolism in human intestinal microsomes and liver microsomes make phosphoramidate 16

91 and favorable metabolism in human intestinal microsomes and liver microsomes.

92 tion of dihydrotestosterone with human liver microsomes and NADPH yielded the 18- and 19-hydroxy prod

93 small degree of re-localization to the light microsomes and nucleus in response to insulin.

94 Metabolite formation in microsomes and plasma could be completely inhibited with

95 good microsomal stability in mouse and human microsomes and provides a good starting point for future

96 lead revealed short metabolic half-lives in microsomes and rapid clearance in the rat.

97 detanib) were characterized by using hepatic microsomes and recombinant proteins.

98 lity when incubated with rat and human liver microsomes and showed no significant cytochrome P450 (CY

99 nd in vitro transportomic assays using yeast microsomes and total plant metabolite extracts, for the

100 with low predicted metabolism in human liver microsomes and which showed prolonged exposure in mice.

101 n vitro (kinase assay), ex vivo (human liver microsomes) and in vivo (mouse) model systems.

102 osomal in vitro assay (Wistar-Han rats liver microsomes), and with concomitant formation of PFCAs, PF

103 moderate metabolic stability in human liver microsomes, and a hERG/DAT affinity ratio = 28.

104 significant cytochrome P450s in cell lysate, microsomes, and bacteria.

105 llowing its incubation in hepatocytes, liver microsomes, and buffers, as illustrated by the identific

106 hows high metabolic stability in human liver microsomes, and displays excellent selectivity in a scre

107 metabolic stability, slow clearance in liver microsomes, and excellent blood-brain barrier permeabili

108 erum, low rates of metabolism in human liver microsomes, and high oral bioavailability in animal mode

109 are stable in simulated gastric fluid, liver microsomes, and human blood and are largely free from bi

110 lture, enhanced metabolic stability in liver microsomes, and improved tolerability in mice.

111 ation in both human and rat plasma and liver microsomes, and is rapidly absorbed following an intrape

112 amide into ceramide in vitro using rat liver microsomes, and the formation of tritiated water after t

113 ediment fractions were incubated with S9 rat microsomes, and the metabolites were extracted with a ne

114 mic reticulum membrane," "cytochrome P450," "microsome," and "oxidation reduction") and moderate CP (

115 uctural 3/4A (NS3/4A) protease from replicon microsomes are potently inhibited by BV.

116 bicistronic human-cyt P450 3A4 (bicis.-3A4) microsomes as enzyme sources.

117 This effect occurred for CFTR channels in microsomes as well as in intact cells and at the same co

118 ing/leak from cardiac and skeletal muscle SR microsomes as well as the function of RyRs in planar bil

119 to cytochrome P450 metabolism using a liver microsome assay.

120 Using cell-based and cell-free microsome assays, we found that the truncated protein la

121 ter than 10 KDa in crude cytosol that affect microsome-associated glucose-6-phosphatase activity.

122 In both whole-cell and microsome-based assays, 4-methoxyindol-3-yl-methanol was

123 ions and alanine substitutions) and in vitro microsome-binding assays with the SUS1 protein to define

124 Mouse liver microsome bioconversion of the methamidoxime prodrugs is

125 LGP2 interacts with MAVS in microsomes, blocking the RIG-I/MAVS interaction.

126 RF3 activation, show that, in resting cells, microsome but not mitochondrial fractions harbor the cen

127 etabolic stability in mouse plasma and liver microsomes but showed only limited oral bioavailability

128 creased with addition of PrCYP79D73-enriched microsomes but was blocked by pretreatment with 4-phenyl

129 creased ROS parameters in the isolated liver microsomes, but isoniazid treatment did not.

130 COPII vesicles are separated from the microsomes by differential centrifugation.

131 Moreover, CerS activity in BAK KO microsomes can be reactivated upon addition of BAK-conta

132 r microsomes and blood plasma, low intrinsic microsome clearance, and low plasma-protein binding.

133 crodialysis infusion of M+4 cortisone to the microsomes coincubated with a proprietary 11beta-HSD1 in

134 ly improved the metabolic stability in liver microsomes compared to SMART.

135 18)F-FTC-146 has a longer half-life in human microsomes, compared with rodents.

136 n of [(14)C]TAG was only possible with yeast microsomes containing both LPCAT1 and DGAT1-1.

137 Yeast microsomes containing CPTL2/CPT3 showed enhanced synthes

138 ve intermolecular experiments with rat liver microsomes {(D)V = 12.5; (D)(V/K) = 10.9} but was with p

139 dipocyte cells, TBMEHP inhibited rat hepatic microsome deiodinase activity and was an agonist for PPA

140 In human liver microsomes, difluoro analogue 5b underwent 10,11-epoxida

141 lines, BGLC3 activity was concentrated in a microsome-enriched fraction but also was present in solu

142 Yeast microsomes expressing EaDAcT possessed acetyl-CoA diacyl

143 cted in dephosphorylation) using insect cell microsomes expressing SERCA2a with or without PLN (wild-

144 accumulate within endoplasmic reticulum (ER)/microsome forms toxic oligomers in mouse and human brain

145 ling of the chimeric proteins in low density microsome fractions isolated from stably transfected 293

146 ed by addition of liver mitochondrial and/or microsome fractions.

147 hat lack endogenous ceramidase activity, and microsomes from ACER2-expressiong yeast cells were used

148 l (5-136) was the major metabolite formed by microsomes from all other species.

149 ittle or no glucuronidation was observed for microsomes from cells overexpressing the UGT2B10*2 varia

150 e activity of glucose-6-phosphatase in crude microsomes from cells with high, normal, or low CF activ

151 n for CYP3A4) was reduced by >50% in hepatic microsomes from CYP3A4-HBN mice compared with controls.

152 information about 11beta-HSD1 activities in microsomes from different mammalian species.

153 otope-labeled cortisone to cortisol in liver microsomes from dog, monkey, and human.

154 hydroxylation was measured ex vivo in liver microsomes from individually genotyped animals.

155 ooled human liver microsomes (HLMs) or liver microsomes from male guinea pig, hamster, monkey, mouse,

156 l-3'-ol (OH-PCB 102), respectively, by liver microsomes from male rats pretreated with different indu

157 Liver and enterocyte microsomes from MTP-deficient animals synthesize lesser

158 Incorporation of human microsomes from multiple organs and selected supersomes

159 The recombinant OLE3 microsomes from Saccharomyces cerevisiae have been shown

160 Isolated liver microsomes from untreated rabbits were treated with 1% B

161 When sealed microsomes from wild type cells and cells depleted of Rf

162 The KM of microsomes from wild-type (WT) UGT2B10-overexpressing ce

163 cal states (i.e., membrane bound as in brain microsomes from wild-type mice or purified GPI-anchorles

164 Finally, human liver microsomes genotyped for rs2108622 demonstrated reduced

165 long half-life in both human and mouse liver microsomes, good permeability, modest protein binding, a

166 demonstrated the functional activity of the microsomes harboring KcsA showing single-channel current

167 was similar to that observed for human liver microsomes (HLM) against both substrates.

168 abromodiphenyl ether (BDE-47) by human liver microsomes (HLM) and recombinant human CYPs, and to iden

169 The role of CYP was assessed in human liver microsomes (HLM) and tyrosol-to-hydroxytyrosol conversio

170 hylphenol, and 3-methylindole in human liver microsomes (HLM) were analyzed by HPLC coupled with Orbi

171 SAHA glucuronidation phenotype, human liver microsomes (HLM) were analyzed for glucuronidation activ

172 to in vitro biotransformation by human liver microsomes (HLM).

173 s carbon electrode materials and human liver microsomes (HLM).

174 n limits (<1 pmol/mg protein) in human liver microsome (HLMs).

175 ort half-life in the presence of human liver microsomes (HLMs) (T1/2 = 2.91 min).

176 te (AM) from 2-oxoclopidogrel by human liver microsomes (HLMs) is greatly affected by the thiol reduc

177 entative chiral PCB, with pooled human liver microsomes (HLMs) or liver microsomes from male guinea p

178 netic studies, CYP2B6 and pooled human liver microsomes (HLMs) were incubated with BDE-47 (0-60 micro

179 The assay employs human liver microsomes (HLMs), immobilized on magnetic beads to faci

180 f metabolic enzymes from human and rat liver microsomes, human and rat liver cytosol, and mouse liver

181 iac and skeletal sarcoplasmic reticulum (SR) microsomes (IC values of 6.6 and 9.9 muM, respectively).

182 hoproteomic analysis of canine pancreatic ER microsomes identified 49 high scoring phosphotyrosine-co

183 Glucose-6-phosphatase is associated with microsomes in both Dictyostelium and mammals.

184 olves incubation of cold compound with liver microsomes in the presence of [14C]potassium cyanide.

185 the metabolism of clopidogrel to human liver microsomes in the presence of four reductants, namely, G

186 old to increase half-life in the presence of microsomes in vitro led to identification of compounds w

187 mbrane association in E. coli and with plant microsomes in vitro without reducing enzymatic activity.

188 In rat liver microsomes in vitro, defluorination of 18F-FCWAY was alm

189 oxycotinine (3HC)-glucuronide in human liver microsomes in vitro.

190 and (2) binding to carbonate-stripped plant microsomes in vitro.

191 The stability of 2 was evaluated in microsomes, in plasma, and toward glutathione.

192 mRNA for these four enzymes, and neutrophil microsomes incorporate arachidonoyl chains into phosphat

193 ndent ATPase activity, which was measured in microsomes incubated with 200, 2, and 0.25 microM Ca(2+)

194 d beta-adduction was observed in mouse liver microsomes incubated with styrene at various concentrati

195 e the percent binding results from the FTUAL microsome incubation experiments, 8:2 FTOH was incubated

196 hydroxylation were observed using CYP2D6-HBN microsomes, indicating a significant role for Cyb5 in th

197 zation during the infection process, scrapie microsomes induced less long-term PrP-res production tha

198 of cultured endothelial cells and placental microsomes is actually TFPIbeta based on (1) migration o

199 s discrepancy with the earlier studies using microsomes is probably due to the known accessibility of

200 gn biologically active interfaces with liver microsomes is suggested to have immense significance in

201 face of endothelial cells and from placental microsomes is TFPIbeta.

202 Transport experiments using microsomes isolated from ABCC1-expressing yeast cells sh

203 In experiments with microsomes isolated from COS-1 cells or HepG2 hepatocyte

204 periments were conducted in vitro with liver microsomes isolated from experimental CKD and control ra

205 Maximum catalytic function is retained in microsomes isolated from High-Five cells and labeled wit

206 Activity assays with microsomes isolated from tobacco plants transiently expr

207 11 had good metabolic stability in rat liver microsomes, it showed modest solubility and blood-brain

208 In isolated cardiac and SkM SR microsomes, K201 slowed the rate of SR Ca(2+) loading, s

209 Interestingly, microsomes labeled with a fluorescent marker were intern

210 ely 4-fold higher than that in camelina seed microsomes lacking CpuDGAT1.

211 from Schizosaccharomyces pombe and hog liver microsomes) leads to the hypothesis that PvdA catalysis

212 nal optimization of metabolic stability with microsomes led to the identification of 15, which displa

213 ibit poor metabolic stability in mouse liver microsomes, likely due to the central tetrahydroquinolin

214 ism in human intestinal microsomes and liver microsomes make phosphoramidate 16 a prospective candida

215 rgets of atypical antibodies to liver/kidney microsome may lead to diagnostic tests for de-novo autoi

216 targeted to both the endoplasmic reticulum (microsomes) (mc CYP2E1) and mitochondria (mt CYP2E1).

217 (d)) for in vivo toxicology outcomes, scaled microsome metabolism/calculated logP for in vivo unbound

218 teins, metabolic stability using human liver microsomes, metabolism by human liver microsomes and hep

219 s in various subcellular fractions including microsomes, mitochondria, and lipid droplets; however, l

220 und that HCMV pUL37x1 is present in purified microsomes, mitochondria, and MAM fractions.

221 alf-lives of greater than 1 h in mouse liver microsomes (MLMs), and were active antinociceptive agent

222 In rat brain microsomes, O(6)-demethylation was inhibited by ketocona

223 uld explain the in vitro covalent binding in microsomes observed across the species.

224 l with concomitant accumulation of TG in the microsome of Adfp-/- cells suggests that ADFP may facili

225 Microsomes of camelina (Camelina sativa) seeds engineere

226 ow levels of intrinsic clearance against the microsomes of four species, good bioavailability (55%) a

227 37- and 3-fold lower than that observed for microsomes of UGT1A4-overexpressing cells against nicoti

228 In the present study, microsomes of UGT2B10-overexpressing HEK293 cells exhibi

229 nium poly(vinylpyridine), DNA, and rat liver microsomes or bicistronically expressed human cyt P450 2

230 ed, apoE concentrated in a subclass of Golgi microsomes or Golgi-derived vesicles that co-migrated wi

231 adioactive 17beta-estradiol with human liver microsomes or recombinant human cytochrome P450 isoforms

232 demonstrated that incubations of human liver microsomes or various human cytochrome P450 isoforms wit

233 sicles that co-migrated with apoB-containing microsomes or vesicles, respectively.

234 In addition to microsomes, Osm1 localizes to the mitochondrial intermem

235 ed SOAT1 and SOAT2 to a similar extent using microsomes prepared from cells disrupted under the stron

236 The assay is specific for FAAH given that microsomes prepared from cells expressing the inactive F

237 irus-infected cells and was also detected in microsomes prepared from HeLa cells.

238 components of technical chlordane, by liver microsomes prepared from male rats treated with corn oil

239 tion and aqueous two-phase separation of the microsome proteins located Rpg1 mainly in the cytosol bu

240 good metabolic stability in plasma and liver microsomes (rat and human), and 32 did not inhibit CYP3A

241 sistent with previous studies of insect-cell microsomes, rat-human chimeric cells, and HeLa cells exp

242 ndole (HONH-AalphaC) formed with human liver microsomes, recombinant human UGT isoforms, and human he

243 ir with reconstituted CYP3A4 and human liver microsomes resulted in a covalent binding stoichiometry

244 ncubating LMP400 and LMP776 with human liver microsomes resulted in two major metabolites of each dru

245 scent substrates were applied to human liver microsomes, results suggested that there was at least on

246 with recombinant CYP4F2 and with human liver microsomes revealed a substrate K(m) of 8 to 10 microM.

247 3-diphenyl-propyl)-nicotinamide in rat liver microsomes revealed extensive oxidative metabolism and a

248 mitochondria but also occur in cytosolic and microsome-rich fractions.

249 point substrate depletion assay in rat liver microsomes (RLM) is employed at the National Center for

250 phase I metabolite was formed by human liver microsomes, seven phase I and II metabolites were formed

251 Mutant ER microsomes show a decreased transfer of lipids to isolat

252 assays with yeast (Saccharomyces cerevisiae) microsomes showed a high specificity of RcsPLA2alpha for

253 d in compound 58 with substantially improved microsome stability and oral bioavailability, as well as

254 A rationale for the improvement in microsome stability and selectivity of inhibitors agains

255 any of the optimized compounds have improved microsome stability, and most are selective against huma

256 ited low cytotoxicity and satisfactory liver microsomes stability and plasma protein binding.

257 n-1 acyltransferase activity in murine liver microsomes stereospecifically and preferentially utilize

258 Finally, liver microsome studies revealed that (18)F-FTC-146 has a long

259 quirrel monkey imaging and human serum/liver microsome studies were performed to gain information abo

260 ocathepsin B is enriched in Golgi-containing microsomes, suggesting a role for the ADP-ribosylation (

261 bserved to assist folding in the presence of microsomes, suggesting that additional co-factors were i

262 as a short half-life (<7 min) in human liver microsomes, suggesting that its limited in vivo efficacy

263 pidly metabolized in rodents and human liver microsomes, suggesting the possibility of rapid in vivo

264 ombinant CYP4F2 (Supersomes) and human liver microsomes supplemented with NADPH converted VK1 to a si

265 metabolic stability in human and mouse liver microsomes, supporting its potential for in vivo use.

266 e favorable metabolic stability in rat liver microsomes supports future studies in in vivo models of

267 abolites after 1 h incubation in human liver microsomes system.

268 ys a good metabolic stability in human liver microsomes (t1/2 approximately 3 h and CLint = 3.5 mL/mi

269 type (WT) CYP2E1-expressing or ER(+) (mostly microsome-targeted) cells.

270 membrane permeable and more stable to liver microsomes than a similar non-statine-containing derivat

271 ve times higher conversion rate in dog liver microsomes than in human and monkey liver microsomes.

272 In kidney microsomes the expression of UGT1A3 was below detection

273 However, when placed in ER-rich microsome, the mutant capsid retained its spherical stru

274 binding of [(3)H]ryanodine to RyR1-enriched microsomes, the mixture and the individual congeners (50

275 the substrate is incubated with human liver microsomes, the reaction is quenched, and the substrates

276 ation experiments, 8:2 FTOH was incubated in microsomes to determine the protein binding associated w

277 +)-methanandamide (MAEA) and FAAH expressing microsomes to evaluate the displacement activity of FAAH

278 an VKOR needs to be preserved in ER-enriched microsomes to exhibit warfarin sensitivity, whereas huma

279 ntified, and the extracts treated with liver microsomes to mimic physiological metabolism, with HPLC

280 tabolizing mosquito P450s, as well as rodent microsomes, to measure labeling specificity, plus cytoch

281 eta-D-glucuronide formation as determined in microsomes treated with bromsulphthalein.

282 Antismooth muscle (ASMA), antiliver kidney microsome type 1 (anti-LKM1), antiliver cytosol type 1 (

283 y at low pH, although stability toward liver microsomes was highly variable.

284 the covalent binding in rat, dog, and human microsomes was identified as a potential indicator for h

285 its formation rate in a panel of human liver microsomes was strongly correlated with CYP3A4 content a

286 ioxidant activity (in liver, heart and brain microsomes) was analysed.

287 Using skeletal muscle microsomes, we examined the effects of BPA and TBBPA on

288 Using wild-type and Cyp3a knockout liver microsomes, we found that 4'-O-deacetylvinorelbine forma

289 Microsomes were used for the first time as sources of cy

290 inducing a net efflux of Ca(2+) from loaded microsomes, whereas BPA exhibited little or no activity

291 ion in the small intestine, we determined in microsomes whether SER access can be modulated by inhibi

292 nd (13)C6-APAP were incubated with rat liver microsomes, which are known to bioactivate APAP to the r

293 accumulation in small intestinal and hepatic microsomes, which influenced the rate of ezetimibe beta-

294 12 was rapidly metabolized by hepatic microsomes, which supports its topical use.

295 t it is efficiently processed in human liver microsomes with a half-life of 2 min.

296 Enrichment of microsomes with cholesteryl esters also inhibits cholest

297 After mixing microsomes with fluorescence-quenching agents and select

298 A is omega-oxidized in the presence of liver microsomes with initial omega-hydroxylation of 2-ClHA.

299 Treatment of rat liver microsomes with S-nitrosoglutathione caused S-nitrosylat

300 rce of 25OHD(3) hydroxylation by human liver microsomes, with the formation of 4beta,25-dihydroxyvita